We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+25.88%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$7.99B
AUM Growth
+$1.36B
Cap. Flow
+$167M
Cap. Flow %
2.09%
Top 10 Hldgs %
82.62%
Holding
149
New
30
Increased
33
Reduced
21
Closed
40

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$40.6M
2
TSRO
TESARO, Inc.
TSRO
+$32.2M
3
BPMC
Blueprint Medicines
BPMC
+$30.2M
4
NKTR icon
Nektar Therapeutics
NKTR
+$25.8M
5
FOLD
Amicus Therapeutics
FOLD
+$22.8M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$21.1M
2
INCY icon
Incyte
INCY
+$18M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$8.37M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$5.83M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$5.72M

Sector Composition

Rank Sector Weight
1 Consumer Staples 43.57%
2 Consumer Discretionary 23.48%
3 Healthcare 17.53%
4 Communication Services 0.15%
5 Materials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAT icon
26
CALL
Caterpillar
CAT
$361B
$29.5M 0.37%
+200,000
New +$31.6M
BLUE
27
DELISTED
bluebird bio
BLUE
$25.6M 0.32%
11,580
– –
INCY icon
28
Incyte
INCY
$25.4B
$25M 0.31%
300,000
-200,000
-40% -$18M
MDCO
29
CALL
DELISTED
Medicines Co
MDCO
$23.1M 0.29%
700,000
– –
NKTR icon
30
CALL
Nektar Therapeutics
NKTR
$2.39B
$21.3M 0.27%
13,333
-60,000
-82% -$77.3M
ANAB icon
31
AnaptysBio
ANAB
$1.54B
$19.8M 0.25%
190,000
+40,000
+27% +$4.51M
AVXS
32
DELISTED
AveXis, Inc. Common Stock
AVXS
$19.8M 0.25%
160,000
+10,000
+7% +$1.19M
ALBO
33
DELISTED
Albireo Pharma Inc
ALBO
$17.8M 0.22%
547,841
+247,841
+83% +$8.35M
FCX icon
34
CALL
Freeport-McMoran
FCX
$86.2B
$17.6M 0.22%
1,000,000
+750,000
+300% +$14.1M
REGN icon
35
CALL
Regeneron Pharmaceuticals
REGN
$72.9B
$17.2M 0.22%
50,000
– –
ALXN
36
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$16.7M 0.21%
150,000
-500,000
-77% -$59.8M
VRTX icon
37
CALL
Vertex Pharmaceuticals
VRTX
$123B
$16.3M 0.2%
100,000
-100,000
-50% -$16.3M
BMRN icon
38
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
$16.2M 0.2%
200,000
+100,000
+100% +$8.58M
SAGE
39
DELISTED
Sage Therapeutics
SAGE
$16.1M 0.2%
100,000
+25,000
+33% +$4.24M
FOLD
40
CALL
DELISTED
Amicus Therapeutics
FOLD
$13.5M 0.17%
900,000
-500,000
-36% -$7.61M
CLVS
41
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$13.2M 0.17%
250,000
+100,000
+67% +$5.83M
AGEN
42
Agenus
AGEN
$276M
$13M 0.16%
140,113
+12,725
+10% +$1.13M
ARGX icon
43
argenx
ARGX
$55.2B
$12.1M 0.15%
150,000
-50,000
-25% -$3.78M
IQ icon
44
iQIYI
IQ
$1.19B
$11.7M 0.15%
+750,000
New +$11.7M
KYNB
45
Kyntra Bio
KYNB
$27.4M
$11.6M 0.14%
+10,000
New +$13.2M
AXDX
46
DELISTED
Accelerate Diagnostics
AXDX
$11.4M 0.14%
50,000
– –
RDUS
47
DELISTED
Radius Health, Inc.
RDUS
$10.8M 0.13%
300,000
-100,000
-25% -$3.61M
GBT
48
DELISTED
Global Blood Therapeutics, Inc.
GBT
$9.66M 0.12%
200,000
-150,000
-43% -$8.37M
XNCR icon
49
Xencor
XNCR
$1.45B
$8.99M 0.11%
300,000
+200,000
+200% +$5.23M
LRMR icon
50
Larimar Therapeutics
LRMR
$377M
$8.94M 0.11%
100,000
+16,667
+20% +$1.41M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2018 Portfolio in Review

As of Q1 2018, Artal Group held 149 positions worth $7.99B, up 21% from $6.63B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group's Q1 2018 filing shows 30 new, 33 increased, 21 reduced and 40 closed positions. Its largest new stake was Kyntra Bio: 10,000 shares worth $11.6M. The largest sale was Neurocrine Biosciences, an estimated $21.1M.

By sector, the portfolio is most concentrated in Consumer Staples at 44% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q1 2018 buy was Kyntra Bio: 10,000 shares worth $11.6M.
  • Artal Group added most to BeOne Medicines Ltd in Q1 2018, an estimated $40.6M increase.
  • Artal Group's biggest Q1 2018 reduction was Incyte, cutting an estimated $18M.
  • Artal Group fully exited Neurocrine Biosciences in Q1 2018, selling an estimated $21.1M.
  • Artal Group's ten largest holdings make up 83% of its $7.99B portfolio in Q1 2018.
  • Artal Group opened 30 new positions and closed 40 in Q1 2018.
  • Artal Group's portfolio value rose 21% quarter-over-quarter to $7.99B.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.